The AKT2 oncogene encodes a protein-serine/threonine kinase containing a pleckstrin homology domain characteristic of many signaling proteins. Recently, it was shown that AKT2 kinase activity can be induced by platelet-derived growth factor through phosphatidylinositol-3-OH kinase, suggesting that AKT2 may be an important signal mediator that contributes to the control of cell proliferation. We previously reported ampli®ca-tion and overexpression of AKT2 in human cancers. To investigate the transforming activity of AKT2, we used a retrovirus-based construct to express AKT2 in NIH3T3 cells. Overexpression of AKT2 was found to transform NIH3T3 cells, as determined by growth in soft agar and tumor formation in nude mice. The oncogenic activity of AKT2 was diminished by truncation of a 70-amino acid proline-rich region at the carboxyl-terminus. To facilitate the characterization of AKT2, we generated monoclonal and polyclonal antibodies against this protein. AKT2 was localized to the cytoplasm by cell fractionation experiments, immunocytochemistry, and immuno¯uorescence. Protein levels were more abundant in mitotic cells than in interphase cells. Western blot analysis of synchronized pancreatic cancer cells demonstrated that the expression level of AKT2 protein in mitotic cells is three to ®vefold higher than in their interphase counterparts. A time-course study of phytohemagglutinin-stimulated lymphocytes revealed that AKT2 mRNA and AKT2 protein levels are highest 48 ± 72 h after addition of mitogen, when cells are actively dividing. These data suggest that AKT2 could play a signi®cant role in cell cycle progression and that the oncogenic activity of overexpressed AKT2 may be mediated by aberrant regulation of cellular proliferation.
Introduction
AKT1 and AKT2 are human homologs of the viral oncogene v-akt. (Staal, 1987) . We previously isolated AKT1 and AKT2 cDNAs and demonstrated that AKT1 is the true human counterpart of v-akt and that AKT2 encodes a closely related protein-serine/threonine kinase (Cheng et al., 1992) . Homologous sequences in the mouse, designated Akt and Akt2, have also been cloned and shown to be highly conserved in mammalian evolution Altomare et al., 1995) . AKT1/Akt and AKT2/Akt2 have also been designated protein kinase B-a and -b or RAC-PKa and RAC-PKb, respectively (Jones et al., 1991; Coer and Woodgett, 1991; Burgering and Coer, 1995; Kohn et al., 1995; Cross et al., 1995) . The AKT1 and AKT2 kinases have signi®cant sequence and structural homology to members of the protein kinase C (PKC) and cyclic adenosine monophosphate-dependent protein kinase families (Bellacosa et al., 1991; Cheng et al., 1992) . However, unlike PKC family proteins, AKT1 and AKT2 possess a Src Homology 2-like (SH2-like) domain at the aminoterminus (Bellacosa et al., 1991; Cheng et al., 1992) . This region is now known to be contained within a pleckstrin-homology (PH) domain, which has been identi®ed in a wide range of proteins involved in cellular signaling and cytoskeletal organization .
AKT2 has been implicated in several types of human malignancy. In particular, ampli®cation and overexpression of AKT2 has been found in 10 ± 20% of ovarian carcinomas (Cheng et al., 1992; Bellacosa et al., 1995) and pancreatic carcinomas (Cheng et al., 1996; Miwa et al., 1996) . Moreover, antisense AKT2 can signi®cantly inhibit the invasiveness and tumorigenicity of pancreatic cancer cells overexpressing this gene (Cheng et al., 1996) . However, alterations of AKT1 have not been consistently observed in any human malignancy. In fact, ampli®cation of AKT1 has been reported in only a single gastric carcinoma (Staal, 1987) . In a previous study, Akt was found to be nononcogenic in nude mice when overexpressed in the nontumorigenic rat T cell lymphoma cell line 5675 (Ahmed et al., 1993) .
Recently, AKT1/Akt was identi®ed as a direct downstream target of phosphatidylinositol-3-OH (PI-3) kinase. Akt can be rapidly activated by a variety of growth factors, such as platelet-derived growth factor (PDGF), epidermal growth factor, basic ®broblast growth factor, and insulin through PI-3 kinase (Franke et al., 1995; Burgering and Coer, 1995; Kohn et al., 1995; Cross et al., 1995; Andjelkovic et al., 1996) , and AKT2 kinase activity also appears to be induced by PDGF (Franke et al., 1995) . These ®ndings suggest that AKT1 and AKT2 may be important signal mediators that contribute to the control of cell proliferation and malignant transformation (Downward, 1995) .
Although AKT2 has been proposed to contribute signi®cantly to the pathogenesis of certain human cancers (Cheng et al., 1992 (Cheng et al., , 1996 Bellacosa et al., 1995; Miwa et al., 1996) , experimental evidence supporting this contention has not been documented to date. In this communication, we describe the results of experiments designed to characterize the growthpromoting potential of AKT2. We show that overexpression of human AKT2 transforms NIH3T3 cells. Similar experiments with a truncated AKT2 cDNA reveal that the carboxyl-terminus of AKT2 is required for transforming activity. In addition, we also present data demonstrating that AKT2 is abundant in mitotic and actively dividing cells, suggesting that AKT2 could play an important role in cell cycle progression and malignant transformation.
Results

Generation of speci®c anti-AKT2 antibodies
To characterize the cellular function of AKT2, a series of monoclonal and polyclonal anti-AKT2 antibodies were produced with bacterial glutathione-S-transferase (GST) fusion proteins containing either the SH2-like region (aa 1 ± 78), helix domain (aa 79 ± 148), or PH domain (aa 1 ± 106) of AKT2. For monoclonal antibodies, 23 hybridomas were isolated that reacted with AKT2 protein produced in bacteria. Six of these were examined for speci®city on Western blots containing puri®ed Akt/AKT1 proteins, four of which reacted speci®cally with AKT2, i.e. they reacted strongly with puri®ed AKT2 but not at detectable levels with puri®ed Akt/AKT1. Three polyclonal antibodies against AKT2 were generated, each of which cross-reacted with Akt/AKT1 to a varying degree. The four monoclonal antibodies and a single polyclonal antibody that showed minimal crossreactivity with Akt/AKT1 were used for subsequent studies.
The polyclonal and monoclonal antibodies were ®rst used for Western blot analysis of protein lysates from 18 pancreatic carcinoma cell lines. Two of these lines (PANC1 and ASPC1) have ampli®cation and overexpression of AKT2 and show high levels of expression of the 56 kD AKT2 protein, whereas AKT2 was barely detectable in the remaining pancreatic cancer cell lines tested (Cheng et al., 1996) . Subsequently, we determined that these anti-AKT2 antibodies can be used successfully in immunoprecipitation studies. PANC1 cells were metabolically labeled with [ 35 S]methionine, lysed, and immunopecipitated with anti-AKT2 monoclonal and polyclonal antibodies. Endogenous AKT2 can be immunoprecipitated with either polyclonal or monoclonal anti-AKT2 antibody, is competed by GST-AKT2 fusion protein, and is not seen in the immunoprecipitates obtained with preimmune serum or anti-CRK antibody (Figure 1 ).
NIH3T3 ®broblasts overexpressing AKT2 are morphologically transformed, grow in medium with low serum, form colonies in soft agar, and are tumorigenic in nude mice
To determine the role of AKT2 in malignant transformation, full-length and C-terminal truncated (70 aa) AKT2 (AKT2-Dtail) were cloned into the LXSN retroviral vector and transfected into mouse NIH3T3 cells. LXSN vector alone and antisense AKT2 and antisense AKT2-Dtail constructs were also introduced into NIH3T3 cells as negative controls. In addition, v-abl was transfected into NIH3T3 cells as a positive control.
In medium containing 10% calf serum, neither fulllength nor truncated AKT2 transfectants formed foci. After G418 selection, pooled transfected cells and clonal cell derivatives expressing AKT2 were generated to determine the eects of such expression on cell morphology and growth. The pooled cells and four clonal cell lines were selected for further analysis. The morphology of the LXSN-AKT2 cells diered from that of parental NIH3T3 (Figure 2a,b) , and NIH3T3 cells transfected with LXSN alone, LXSN-AKT2-Dtail, antisense AKT2, or antisense AKT2-Dtail. The LXSN-AKT2-transfected cells were more refractile, rounded, and larger than the negative control cells.
The growth properties of LXSN-AKT2 cells and LXSN-AKT2-Dtail cells were evaluated in medium containing a low concentration of serum (Persons et al., 1988; Chauhan et al., 1993) . The LXSN-AKT2-transfected cells, including pooled cells and each of the four clonal cell lines, grew well in medium with 0.1% calf serum during a 4 week observation period. In this medium, LXSN-AKT2-transfected cells formed colonies that were similar to those formed by v-abl transformed cells (Figure 2d ,e), whereas parental cells and LXSN-AKT2-Dtail and LXSN transfected cells did not (Table  1) . These results suggest that AKT2-transformed cells have a reduced serum dependence for growth.
Anti-AKT2
Anti-CRK Anti-AKT2+GST-AKT2 (Table 1) .
To investigate the tumorigenic activity of AKT2, pooled transfectants and clonal cell lines were injected subcutaneously into nude and scid mice. All mice inoculated with LXSN-AKT2-transfected cells formed tumors within 10 ± 28 days following injection. Tumors developed sooner in mice given a higher inoculum (Table  1) . Western blot analysis revealed expression of AKT2 protein only in LXSN-AKT2-transfected cells and tumors ( Figure 3 ; Table 1 ) and in LXSN-AKT2-Dtail transfected cells (Table 1) . The transfection and tumorigenicity experiments were repeated on a second occasion using scid mice, and very similar results were obtained.
Subcellular localization of AKT2
The subcellular localization of AKT2 was examined in a normal human ®broblast cell line, AKT2-transfected NIH3T3 cells, and three tumor cell lines (PANC1, ASPC1, Ovcar 3) previously shown to exhibit ampli®cation and overexpression of AKT2 (Cheng et al., 1992 (Cheng et al., , 1996 . Immunocytochemical staining and immuno¯uorescence with anti-AKT2 polyclonal and monoclonal antibodies revealed that AKT2 protein localizes to the cytoplasm in normal and tumor cells ( Figure 4 ) as well as in AKT2-transfected NIH3T3 cells (data not shown). Cell fractionation studies also showed that AKT2 protein was only present in the cytosolic fraction (data not shown).
Expression of AKT2 in mitotic and interphase cells
Interestingly, the immunocytochemistry and immunouorescence studies revealed more abundant AKT2 protein within cells in various stages of mitosis (including prophase, metaphase, anaphase and telophase) than in interphase cells (Figure 4) . Confocal microscopy and quantitative image analysis revealed that in both tumor and normal cells the average intensity of total cellular immuno¯uorescence was two to threefold higher in mitotic cells than in interphase cells, suggesting that the amount of AKT2 protein uctuates in a cell cycle-dependent manner and is increased in mitosis.
To con®rm the cytological evidence suggesting that AKT2 protein is more abundant in mitotic cells, we prepared mitotic and interphase cells from PANC1 cells treated with nocodazole, which arrests cells in mitosis. Equal amounts of protein from mitotic and interphase cells were subjected to Western blot analysis. The level of AKT2 protein was three to ®vefold higher in mitotic cells than in interphase cells, whereas the level of AKT1 did not dier in these two cell populations ( Figure 5 ).
Additional evidence that AKT2 is associated with mitotic activity was obtained by a lymphocyte timecourse study. Phytohemagglutinin (PHA)-stimulated peripheral blood lymphocytes from two healthy donors were collected at various time points following addition of mitogen. Northern and Western blot analyses revealed that the levels of AKT2 mRNA and AKT2 protein are highest at 48 ± 72 h (Figure 6a ), when PHA-stimulated lymphocytes are actively dividing (Richman, 1980) . In contrast, no change in the level of AKT1 protein was detected in these cells (Figure 6b ).
To determine whether AKT2 activity is elevated in mitotic cells, we performed an in vitro kinase assay with equal amounts of protein from mitotic and interphase PANC1 cells. This experiment revealed that AKT2 kinase activity is approximately ®vefold higher in mitotic cells than in their interphase counterparts ( Figure 5 ), which parallels the elevated AKT2 protein level observed in mitotic cells. 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 1/6 2/6 0/6 1/6 1/6 1/6 1/6 2/6 0/6 1/6 1/6 2/6 0/6 0/6 1/6 1/6 0/6 1/6 
Discussion
In this report, we demonstrate that overexpression of AKT2 in NIH3T3 cells results in a transformed phenotype, as judged by several criteria, including proliferation in medium containing minimal serum, anchorage-independent growth, and tumor formation in nude mice. The oncogenic activity of overexpressed AKT2 can be abolished by truncation of 70 aa from the C-terminus, suggesting that this region may contain an important functional sequence involved in AKT2 activity and, therefore, potentially malignant transformation. Sequence analysis revealed that this region is proline rich (6/70 aa) and that a SH3-binding motif (X-P-X-X-P-X) (Pawson, 1995; Alexandropoulos et al., 1995) resides in this region, suggesting that AKT2 may interact with SH3 domain-containing proteins that may mediate AKT2 signaling. The proline-rich region of AKT2 is similar to a binding site for the SH3 domain of the adapter protein CRK (Alexandropoulos et al., 1995) . However, AKT2 was not immunoprecipitated with an anti-CRK antibody (Figure 1 ). Cancer is considered to be a disorder of the cell cycle (Pines, 1995) . A number of cell cycle regulators have been identi®ed, some of which are implicated as products of either oncogenes or tumor suppressor genes. For example, p53, Rb, p16, and the cyclins D1, D2 and D3 all are involved in the G1/S transition. The oncoproteins Mos and Ras can arrest Xenopus embryonic cell cleavage in mitosis and maintain high levels of M-phase-promoting factor (Sagata et al., Daar et al., 1991) . Moreover, a number of other oncoproteins such as Src, Raf, Ras, erbB1 and erbB2 mediate mitogenic signals and can regulate cell cycle progression (Muller et al., 1993) . Recent studies have shown that AKT1/Akt can be rapidly activated by various mitogenic growth factors through PI-3 kinase (Franke et al., 1995; Burgering and Coer, 1995; Kohn et al., 1995; Cross et al., 1995; Andjelkovic et al., 1996) and AKT2 can also be induced by PDGF (Franke et al., 1995) . These data suggest that AKT1/Akt and AKT2 may contribute to the control of cell proliferation. In this report, we demonstrate that AKT2 is elevated in mitotic cells, indicating that this protein uctuates in a cell cycle-dependent manner. Moreover, AKT2 mRNA and AKT2 protein levels are elevated in actively dividing lymphocytes, whereas AKT1 levels are unchanged, suggesting that AKT2 could play a role in cell cycle progression. Thus, overexpression of AKT2 could contribute to aberrant cell growth associated with transformation in vitro and tumor formation or progression in vivo. In vitro studies by Ahmed et al. (1993) demonstrated that Akt is not tumorigenic when overexpressed in the nontumorigenic rat T cell lymphoma cell line 5675, whereas v-akt-expressing 5675 cells are highly oncogenic when inoculated in nude mice. Since v-akt arose by way of an in-frame fusion of Gag and Akt, the oncogenic dierence between v-akt and Akt may be due to dierences in their subcellular localization, i.e. Akt is restricted to the cytoplasm, whereas v-akt is distributed almost equally among the plasma membrane, cytoplasm, and nucleus. This association of vakt with the plasma membrane and the nucleus may permit its interaction with target molecules mediating oncogenic signals (Ahmed et al., 1993) . Interestingly, AKT2 is tumorigenic when overexpressed in NIH3T3 cells even though it remains localized in the cytoplasm (data not shown), suggesting that the mechanism by which AKT2 transforms cells diers from that of v-akt.
In addition, AKT2 has been shown to be ampli®ed and overexpressed in 10 ± 20% of ovarian and pancreatic carcinomas as well as in a case of non-Hodgkin's lymphoma (Cheng et al., 1992 (Cheng et al., , 1996 Bellacosa et al., 1995; Miwa et al., 1996; Arranz et al., 1996) . However, alterations of AKT1 have been observed in only a single gastric tumor to date (Staal, 1987) . The apparent dierences between Akt/AKT1 and AKT2 with respect to their oncogenic activity and involvement in human malignancy suggest that the signal transduction pathways of these two closely related proteins may dier, particularly with regard to their downstream targets or substrates.
Finally, we have generated several speci®c anti-AKT2 monoclonal antibodies. We have tested several commercially available anti-AKT2 antibodies and have found that each reacts with both AKT1 and AKT2. The use of such antibodies can pose problems in interpreting certain experimental data, particularly since AKT1 and AKT2 proteins have the same mobility on SDS ± PAGE. Thus, our monoclonal antibodies will be useful for future studies of AKT2 function.
Materials and methods
Expression constructs and DNA transfections
The vector (LXSN) utilized in the generation of the expression constructs contains a promoter from the 5' long terminal repeat of the Moloney murine leukemia virus and a neomycin resistance gene suitable for the selection of transfectants. The AKT2 construct expresses the entire AKT2 open reading frame (aa 1 to 481). AKT2-Dtail expresses a truncated AKT2 protein (aa 1 to 411) with 70 aa deleted from the carboxy terminus. As controls, antisense AKT2 and antisense AKT2-Dtail constructs were also generated. Transfections were carried out in NIH3T3 ®broblasts. Lipofectin Reagent (Gibco BRL) was used to transfect cells with 10 mg of each DNA construct as described previously (Cheng et al., 1996) . Forty-eight h after transfection, G418 was added to the medium (Dulbecco's modi®ed Eagle medium [DMEM] supplemented with 10% calf serum) at a concentration of 400 mg/ml. Individual colonies were isolated and expanded for further analysis.
Preparation of mitotic PANC1 cells
PANC1 cells were grown as monolayers at 378C in DMEM containing 10% fetal calf serum. To isolate mitotic cells, nocodazole (methyl[5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl] carbamate; Sigma) was added to the culture medium at a ®nal concentration of 0.4 mg/ml. After incubating for 14 h in the presence of nocodazole, approximately 50% of the cells were rounded and readily detached following gentle tapping of the¯asks and washing with medium. The¯oating cells were harvested by centrifugation and washed in cold phosphate buered saline (PBS) prior to lysis. An aliquot of the cell suspension was ®xed in methanol, dropped onto a clean glass slide, and allowed to air-dry; microscope analysis con®rmed that more than 90% of these cells were in mitosis. Interphase cells that remained ®rmly attached to the surface of thē asks were washed with cold PBS and then lysed with NP-40 buer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 20 mM EDTA, 0.5% NP-40, 1 mM phenylmethylsulfonyl uoride [PMSF], 2 mg/ml aprotinin, 2 mg/ml leupeptin, 1 mM benzamidine, and 10 mg/ml trypsin inhibitor).
Stimulation of lymphocyte mitotic activity
Peripheral blood mononuclear cells (PBMC) were isolated from two healthy donors by Ficoll (Pharmacia LKB) density gradient centrifugation. Subsequent to incubation on gelatin-coated¯asks, the PBMC composition was determined by cell-sorter analysis to be 89% lymphocytes and 11% monocytes. The PBMC population was resuspended in RPMI 1640 medium supplemented with 15% fetal calf serum and 2 mM L-glutamine. Cells were plated in 6-well culture dishes at a density of 2610 6 cells/ml in the presence of 0.2% PHA (Gibco BRL) to stimulate lymphocyte mitogenic activity. PBMCs were collected at various times (0.5 h to 72 h for RNA; 1 day to 7 days for protein) after addition of PHA for analysis of gene expression.
GST fusion protein and generation of anti-AKT2 antibodies
The SH2-like region (aa 1 ± 78), helix domain (aa 79 ± 148), and PH domain (aa 1 ± 106) of AKT2 were each introduced into the prokaryotic expression vector pGEX-3X (Pharmacia). The resulting constructs direct the synthesis of GST-SH2-like, GST-helix, and GST-PH fusion proteins. Expression and puri®cation of the GST fusion proteins were essentially as described by Smith and Corcoran (1994) . Brie¯y, logarithmically growing cultures of E. coli JM83 transformed with the pGEX-3X recombinant were incubated with 0.1 mM isopropyl-b-D-thiogalactopyranoside at 378C for 6 h. The cells were then pelleted, resuspended in ice-cold PBS containing 2 mg/ml aprotinin, 1 mg/ml leupeptin, and 1 mM PMSF, and then sonicated on ice. Debris was removed by centrifugation, and the supernatant was then applied to a glutathione sepharose 4B column (Pharmacia). GST fusion protein was eluted from the column and separated by SDS-polyacrylamide gel electrophoresis and puri®ed with an Electro-Eluter (Bio-RAD).
Polyclonal anti-AKT2 antibodies were raised in New Zeealand White rabbits. Approximately 300 mg of GST fusion protein was used to immunize each rabbit every 2 weeks; rabbits were bled 10 days after each booster injection. The antibodies were then anity puri®ed. Monoclonal antibodies were generated by standard methods (McKenzie et al., 1989) . Female CB6 F1 mice were immunized by intraperitoneal injection on three successive occasions with 20 mg of GST fusion protein. Hybridomas were produced as described (McKenzie et al., 1989) . Test bleeds and hybridomas were screened for anti-AKT2 reactivity by ELISA, using puri®ed GST-SH2-like, GST-helix or GST-PH coated on plates at a concentration of 500 ng/ml. Antibody-antigen complexes were detected by horseradish peroxidase-conjugated goat anti-mouse IgG (Boehringer Mannheim).
Metabolic labeling of cells, immunoprecipitation, and immunoblotting
For metabolic labeling with [
35 S]methionine, subcon¯uent (50 ± 70%) PANC1 cells were washed twice with prewarmed labeling media (methionine-and cysteine-free DMEM [ICN] supplemented with 10% dialyzed fetal bovine serum). After a 30-min incubation with labeling media, [
35 S]methionine (Trans 35 S-label, ICN) was added to the medium to a ®nal concentration of *200 mCi/ml and then incubated for an additional 6 h prior to lysis. All immunoprecipitation steps were carried out at 48C. Cells from a 75 cm 2¯a sk were washed twice with cold PBS and scraped into NP-40 lysis buer and then lysed by rotating for 20 min. Nuclei were removed by centrifugation at 14 000 g for 5 min, and lysates were precleared by mixing with 20 ml of a 50% suspension of protein A-protein G (2:1) agarose (Gibco BRL) for 20 min. Following the removal of the beads by centrifugation, the lysates were incubated with antibody in the presence of 30 ml of protein A-protein G agarose slurry for 6 h. The resulting immunoprecipitates were washed three times in lysis buer and once in 50 mM Tris-HCl (pH 8.0) at room temperature, resuspended in SDS sample buer, and separated on SDS-polyacrylamide gels. The gels were ®xed with 10% glacial acetic acid and 30% methanol for 30 min, enhanced by impregnating with autoradiography enhancers (DuPont) for 30 min, and precipitated in water for 15 min. Enhanced gels were dried and exposed to X-ray ®lm.
Immunoblotting was carried out as described previously (Cheng et al., 1996) . Brie¯y, equivalent amounts of protein from each cell line were separated on a SDS-polyacrylamide gel and transferred onto Hybond-C Super membrane (Amersham) using a Trans-Blot Semi-Dry Transfer Cell (Bio-Rad). Following overnight incubation in 5% dry milk in PBS at 48C, the ®lters were exposed for 1 h at room temperature to anti-AKT2 antibody in blocking solution (1% dry milk), followed by washing. Detection of AKT2 protein was carried out with the ECL Western Blotting Analysis System (Amersham).
In vitro kinase assay
Immunoprecipitation was performed for 4 h using anti-AKT2 antibody. Immunopecipitates were washed three times with lysis buer, once with water, and once with kinase buer (20 mM HEPES-NaOH, 10 mM MgCl 2 , 10 mM MnCl 2 , [pH 7.4]). Kinase assays were carried out in 50 ml kinase buer containing 10 mCi [g-32 P]ATP, 2 mM cold ATP, and 25 mg myelin basic protein or 25 mg histone H2B. After incubation at 308C for 30 min, samples were analysed by 12% SDS ± PAGE and then autoradiographed. For measurement of protein kinase activity, the phosphorylated substrate bands were excised from the dried gel, and radioactivity was counted by scintillation spectrophotometry.
Immunocytochemical staining, immuno¯uorescence, and cell fractionation
Immunocytochemical staining was performed with an ABC kit according to the manufacturer's recommendations (Vector). Immuno¯uorescence was carried out as described by Willingham (1990) . Cells were grown overnight on tissue culture chamber slides. After ®xation with 3% paraformaldehyde at room temperature for 10 min, the cells were washed in PBS containing 0.1% saponin (Sigma). Nonspeci®c binding was blocked by treatment with 5% serum, 1% BSA, and 0.1% saponin for 1 h at 378C. Anti-AKT2 antibodies were used at a 1:100 dilution. The cells were washed thoroughly in PBS containing 0.1% saponin. Goat anti-rabbit or anti-mouse IgG-FITC conjugate was used as the secondary antibody, followed by extensive washing in PBS. The cells were then counterstained with propidium iodide (Oncor) and observed with a Zeiss Axiphot uorescence microscope. Images were captured on a cooled CCD camera (Photometrics) connected to a Macintosh computer work station. Images of propidium iodide staining and FITC signals were merged using Oncor Image software, version 1.6. In addition,¯uorescence corresponding to anti-AKT2 binding sites was quanti®ed in single cells (approximately 20 mitoses and 20 interphases from normal ®broblasts and a similar number from PANC1 cells) using a Bio-Rad MRC 600 confocal laser photometer. FITC was excited with a 25 mW krypton/argon laser at 10% transmission, and lines at 488 nm and 568 nm were used for FITC and propidium iodide, respectively. The fluorescence emission was recorded at wavelengths greater than 515 nm. The image scans were obtained with pixels of 0.3 mm 2 using 4095 relative levels of¯uorescence with a 606oil/NA 1.3 objective and an optical thickness of 0.7 mm.
Cell fractionation studies were carried out as described by Smith et al. (1993) . cells were centrifuged at 200 g and washed three times with PBS containing 0.5 mM CaCl 2 . The pellet was resuspended in lysis buer (5 mM Tris-HCl [pH 7.8], 2 mM MgCl 2 . The nuclei and unlysed cells were pelleted by centrifugation at 500 g. The pellet was washed once with lysis buer and saved as the`nuclear fraction', The supernatant was then centrifuged at 1000 000 g for 1 h; the resulting pellet was designated the`membrane fraction', and the supernatant was designated the`cytosolic fraction.'
Soft agar assay and tumorigenicity in nude mice
For soft agar assays, three scalar concentrations (1610 3 , 1610 4 , 1610 5 ) of the pooled AKT2-transfected cells were suspended in 2 ml of 0.35% (wt/vol) agar containing DMEM/20% fetal calf serum, overlaid onto a 0.5% agar solution in 35 mm plates. The cultures were fed once a week for 4 weeks.
Tumor formation in 6-week old female nude/nude mice and scid mice was tested by subcutaneous inoculation and assessed for 6 weeks. Parental NIH3T3 cells and cells transfected with LXSN, LXSN-AKT2 or LXSN-AKT2-Dtail were each injected into 6 animals at 2610 6 cells/mouse and another six animals at 6610 6 cells/mouse. Tumor measurements were made with linear calipers in two orthogonal directions by the same observer. To establish cell lines derived from individual tumors that formed in mice, portions of each tumor were chopped into ®ne pieces and treated with collagenase type I (400 units/ml) for 2 h. The cell suspension was centrifuged, washed twice with DMEM medium without serum, and cultured at 378C in DMEM medium containing 10% calf serum.
